Project Grant R01CA292084
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$683K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $734,435 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in acute myeloid leukemia (AML). The key objectives are to: 1) determine how increased AMP synthesis via the ADSS2 enzyme promotes resistance to BH3 mimetics in AML, 2) define how ADSS2-mediated AMPK activation antagonizes BH3 mimetic-induced apoptosis, and 3)...
The National Cancer Institute, under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $404,995 project grant to Cambium Oncology LLC to develop a novel immunotherapeutic for the treatment of acute myeloid leukemia (AML). The funding will support preclinical studies to determine the potency, anti-leukemia activity, stability, and pharmacokinetics of Cambium Oncology's lead drug candidate, ANT308-FC3 fusion. This fusion protein is designed to enhance T-cell activation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Case Western Reserve University (CWRU) to advance research on targeting leukemia stem cells (LSCs) as a novel approach to treating acute myeloid leukemia (AML). The primary objectives are to investigate the impacts of newly developed small molecule nuclear heat shock transcription factor 1 (HSF1) degraders on LSC self-renewal, identify sensitive and resistant AML...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $443,220 to the Beckman Research Institute of the City of Hope to investigate the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The 5-year project aims to consolidate the importance of METTL1 function in AML pathogenesis, understand how the METTL1/tRNA/HCK signaling axis facilitates leukemia stem cell...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Beckman Research Institute of the City of Hope to conduct research on a novel combination therapy for relapsed/refractory acute myelogenous leukemia (AML) in patients over 60 years old. The key objectives are to: 1) Establish the appropriate dosing of anti-CD38 targeted alpha therapy (225Ac-DOTA-daratumumab) when combined with total marrow irradiation (TMLI), fludarabine,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to identify and characterize different leukemia initiating cell (LIC) subtypes and their vulnerabilities in acute myeloid leukemia (AML) in order to develop more effective and durable therapies. The $387,630 award, which spans from July 2024 to June 2029, will fund studies to mechanistically understand how inhibiting inhibitor of apoptosis proteins (IAP) using SMAC...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Regents of the University of California, San Francisco (UCSF) to complete rigorous preclinical validation of a novel radioimmunotherapy (RIT) for the treatment of acute myeloid leukemia (AML). The key objectives of this $678,101 award, spanning March 2025 to February 2030, are to evaluate the preclinical efficacy, toxicity, and combination efficacy of a 7065-based RIT...
This Project Grant award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program will support research at Case Western Reserve University to investigate a novel approach to treat acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish a mechanistic understanding of how hyperactivation of the mTOR pathway can be leveraged to enhance the efficacy of proteasome inhibitors in killing AML cells. The research will map the...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to investigate the mechanisms underlying the increased risk of hematological malignancy (HM) in patients with sickle cell disease, including those who have undergone gene therapy or hematopoietic stem cell transplant. The research aims to determine if oxidative stress-induced DNA damage in...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...